First Horizon Advisors Inc. Has $56,000 Stock Holdings in HealthEquity, Inc. (NASDAQ:HQY)

First Horizon Advisors Inc. reduced its holdings in shares of HealthEquity, Inc. (NASDAQ:HQY) by 20.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 852 shares of the company’s stock after selling 225 shares during the quarter. First Horizon Advisors Inc.’s holdings in HealthEquity were worth $56,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in HQY. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of HealthEquity in the fourth quarter valued at about $29,000. DekaBank Deutsche Girozentrale bought a new position in shares of HealthEquity during the 3rd quarter worth approximately $41,000. Fifth Third Bancorp boosted its stake in shares of HealthEquity by 36.5% in the 3rd quarter. Fifth Third Bancorp now owns 602 shares of the company’s stock worth $44,000 after buying an additional 161 shares during the last quarter. Operose Advisors LLC bought a new position in shares of HealthEquity in the third quarter valued at approximately $44,000. Finally, Covestor Ltd increased its position in shares of HealthEquity by 92.9% during the third quarter. Covestor Ltd now owns 1,119 shares of the company’s stock valued at $82,000 after acquiring an additional 539 shares during the last quarter. 99.55% of the stock is owned by institutional investors.

HealthEquity Price Performance

Shares of NASDAQ:HQY opened at $80.38 on Wednesday. HealthEquity, Inc. has a 12 month low of $53.15 and a 12 month high of $84.49. The company has a current ratio of 4.76, a quick ratio of 4.76 and a debt-to-equity ratio of 0.43. The stock has a market cap of $6.90 billion, a P/E ratio of 125.59, a P/E/G ratio of 1.28 and a beta of 0.55. The company has a 50 day moving average of $80.66 and a 200 day moving average of $74.72.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Tuesday, March 19th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.08. The firm had revenue of $262.39 million during the quarter, compared to analyst estimates of $258.56 million. HealthEquity had a net margin of 5.57% and a return on equity of 6.91%. As a group, sell-side analysts forecast that HealthEquity, Inc. will post 2.12 EPS for the current fiscal year.

Insider Activity

In other news, EVP Delano Ladd sold 2,558 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $82.59, for a total value of $211,265.22. Following the transaction, the executive vice president now owns 47,438 shares of the company’s stock, valued at approximately $3,917,904.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, EVP Delano Ladd sold 2,558 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $82.59, for a total value of $211,265.22. Following the completion of the transaction, the executive vice president now directly owns 47,438 shares in the company, valued at approximately $3,917,904.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jon Kessler sold 33,765 shares of the stock in a transaction dated Friday, March 22nd. The shares were sold at an average price of $79.81, for a total value of $2,694,784.65. Following the transaction, the chief executive officer now owns 126,635 shares in the company, valued at $10,106,739.35. The disclosure for this sale can be found here. In the last 90 days, insiders sold 71,322 shares of company stock worth $5,682,895. 2.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

HQY has been the topic of several research analyst reports. BTIG Research boosted their price objective on HealthEquity from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. Royal Bank of Canada increased their price target on shares of HealthEquity from $90.00 to $92.00 and gave the company an “outperform” rating in a research report on Wednesday, March 20th. Barrington Research reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of HealthEquity in a research report on Friday, March 22nd. Bank of America increased their target price on shares of HealthEquity from $93.00 to $97.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. Finally, Barclays lifted their price target on shares of HealthEquity from $84.00 to $104.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat, HealthEquity has a consensus rating of “Moderate Buy” and a consensus target price of $96.17.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.